Plasma factor XIII activity in patients with disseminated intravascular coagulation.
The objective of this study was to investigate the correlation between factor XIII (FXIII) activity and disseminated intravascular coagulation (DIC) parameters and also to evaluate the clinical usefulness of DIC diagnosis. Citrated plasma from eighty patients with potential DIC was analyzed for FXIII activity. The primary patient conditions (48 male and 32 female, mean age, 51 years) were malignancy (n = 29), infection (n = 25), inflammation (n = 6), heart disease (n= 3), thrombosis (n = 2), injury (n = 2), and other miscellaneous conditions (n = 13). FXIII testing was performed using the CoaLinkTM FXIII Incorporation Assay Kit (PeopleBio Inc.). Among 80 patients who were suspected to have DIC based on clinical analysis, 46 (57.5%) fulfilled the overt DIC criteria (DIC score > = 5) according to the International Society of Thrombosis and Haemostasis. FXIII levels in the plasma were significantly decreased in overt DIC compared to non-overt DIC patients (mean 75.1% and 199.7% respectively, p < 0.0001). Interestingly, we found a significant inverse correlation between DIC scores and FXIII activity. In addition, FXIII activity significantly correlated with other hemostatic markers that included platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer. FXIII levels were significantly lower in patients with liver or renal dysfunction. In conclusion, FXIII cross-linking activity measurements may have differential diagnostic value as well as predictive value in patients who are suspected to have DIC.
Song
Jae Woo
JW
Department of Laboratory Medicine, Yongdong Severance Hospital, 146-92 Dogok-dong, Kangnam-gu, Seoul 135-720, Korea.
Choi
Jong Rak
JR
Song
Kyung Soon
KS
Rhee
Ji-Hyuk
JH
D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D003432:Cross-Linking Reagents / Q000494:pharmacology / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000097:blood* / Q000175:diagnosis*; D005176:Factor XIII / Q000096:biosynthesis*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000096:biosynthesis; D006487:Hemostasis; D006801:Humans; D007249:Inflammation; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000473:pathology; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011517:Prothrombin Time
D003432:Cross-Linking Reagents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005176:Factor XIII